source
- Roche drops anti-myostatin obesity drug after mid-stage trial shows limited weight lossRoche announced it will stop development of its anti-myostatin obesity candidate emugrobart after an interim analysis of the Phase 2 GYMINDA trial showed it is unlikely to produce meaningful weight…
- AstraZeneca commits $2 billion to partner Summit Therapeutics on bispecific cancer antibodyAstraZeneca has announced a $2 billion investment to work with Summit Therapeutics. The deal will fund the testing of Summit’s bispecific antibody, ivonescimab, which targets both PD‑1 and VEGF pat…